Transfusion and Apheresis Science最新文献

{"title":"Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)","authors":"Anna Colpo ,&nbsp;Monia Marchetti ,&nbsp;Irene Bianco ,&nbsp;Fabio Cruciani ,&nbsp;Francesco Ipsevich ,&nbsp;Mauro Montanari ,&nbsp;Maria Teresa Lupo Stanghellini ,&nbsp;on behalf of the Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)","doi":"10.1016/j.transci.2024.103990","DOIUrl":"10.1016/j.transci.2024.103990","url":null,"abstract":"<div><p>These guidelines represent a GRADE-method revision of the recommendations produced by the Italian Society of Hemapheresis and Cell Manipulation (SIDEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) in 2013. Since 2013 several studies have been published that have strengthened the role of ECP in the management of GVHD. Thus, it was deemed appropriate to proceed with an update, with the aim to define uniform criteria for the application of ECP in adult and pediatric patients affected by GVHD throughout the national territory, in line with international guidelines, in maintaining of high standards of safety for patients and quality of the procedures provide. Post-HSCT GvHD therapies other than ECP and ECP therapy of other diseases, such as CTCL, are not covered by these guidelines.The development panel for this guideline includes professionals from various specialties who routinely interact in the management of the patient with GVHD, namely the transfusionist, the adult and pediatric hematologist, and the hospital pharmacist. A hematologist experienced in systematic reviews and GRADE guideline development ccordinated the development process, and an experienced transfusionist coordinated the assignment of tasks and reporting. External reviewers of the guideline included a patient representative.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103990"},"PeriodicalIF":1.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142087874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of continuous negative pressure suction combined with autologous platelet-rich gel on the levels of CRP, IL-6, wound healing and length of stay in clients with diabetic foot","authors":"Lan Zhang ,&nbsp;Yuan Zhao ,&nbsp;Xiaoyun Fan,&nbsp;Dongliang Liu,&nbsp;Yan Geng","doi":"10.1016/j.transci.2024.103989","DOIUrl":"10.1016/j.transci.2024.103989","url":null,"abstract":"<div><h3>Objective</h3><p>Continuous passive pressure suction and APG gel therapy effect diabetic foot IL-6, CRP, wound healing, and hospitalization.</p></div><div><h3>Methods</h3><p>Clinicopathological data from 102 diabetic foot ulcer patients treated at our institution between March 2018 and May 2022 was examined. Tables generated 51 joint and controlling teams randomly. The observation team received passive pressure suction and APG gel whereas the controlled team received conventional treatment. Teams monitored therapy outcomes, adverse responses, wound healing, hospital stay, and costs. Both teams compared blood uric acid, cystatin C, homocysteine, and serum IL-6, IL-10, and CRP before and after medication.</p></div><div><h3>Results</h3><p>The joint team had higher hospitalization costs, shorter stays, and faster wound healing than the controlled team. Diaparity was significant (P &lt; 0.05). The united team worked 100 %, unlike the controlling team. This difference was significant (P &lt; 0.05). Both teams showed significant decreases in CRP, IL-6, and IL-10 levels after therapy (P &lt; 0.05). After therapy, both the combined and controlled teams had substantial differences in blood CRP, IL-6, and IL-10 levels (P &lt; 0.05). Both teams had significantly decreased uric acid, cystatin C, and homocysteine after treatment. The combined team showed significantly decreased uric acid, cystatin C, homocysteine levels following therapy compared to the control team (P &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>The joint team experienced considerably fewer adverse events (3.92 % vs. 17.65 %) than the controls team (P &lt; 0.05). Permanent passive pressure suction and APG gel therapy lower inflammatory response, blood uric acid, cystatin C, and homocysteine, speeding wound healing, reducing side effects.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103989"},"PeriodicalIF":1.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001605/pdfft?md5=d51a6d22580fffd15948e33e78b4063b&pid=1-s2.0-S1473050224001605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation","authors":"Francesco Lanza","doi":"10.1016/j.transci.2024.103985","DOIUrl":"10.1016/j.transci.2024.103985","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103985"},"PeriodicalIF":1.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001563/pdfft?md5=f0c8df4dc0664650182bab6e1160337e&pid=1-s2.0-S1473050224001563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141964633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial comment: Reflections on current position and future trends on Immunoglobulins therapy","authors":"Jerard Seghatchian","doi":"10.1016/j.transci.2024.103986","DOIUrl":"10.1016/j.transci.2024.103986","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103986"},"PeriodicalIF":1.4,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Safe Blood Transfusion Self‐Efficacy Scale for nurses: Validity and reliability study","authors":"Gülsüm Dülger ,&nbsp;Gülten Karahan Okuroglu","doi":"10.1016/j.transci.2024.103984","DOIUrl":"10.1016/j.transci.2024.103984","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of the study is to develop a scale to measure nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div><div><h3>Methods</h3><p>This study, applied in methodological design, was conducted in a public university hospital in Istanbul between March-April 2021. The sample included 372 nurses. A draft form consisting of 75 items was prepared. Content validity, construct validity, distinctiveness, internal consistency reliability, two-half test reliability, test-retest, and item analysis methods were used to determine the psychometric properties of the scale.</p></div><div><h3>Results</h3><p>The exploratory factor analysis showed that the scale had a four-factor structure that explained 71.36 % of the total variance. The factor loads of 49 items were found to vary between 0.50 and 0.92. The item-total correlations were found to be between 0.55 and 0.92. The Cronbach's alpha value for the whole scale was 0.96.</p></div><div><h3>Conclusion</h3><p>The results of the analysis show the items constituting Safe Blood and Blood Products Transfusion Self-Efficacy Scale have validity and reliability criteria that can measure the nurses' self-efficacy levels regarding safe blood transfusion practice.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103984"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards personalized and rational use of immunoglobulins amid expanding indications and shortages","authors":"Hadi Goubran ,&nbsp;Gaafar Ragab ,&nbsp;Jerard Seghatchian ,&nbsp;Thierry Burnouf","doi":"10.1016/j.transci.2024.103987","DOIUrl":"10.1016/j.transci.2024.103987","url":null,"abstract":"<div><p>The development of intravenous IgG (IVIG) formulations in the 1970s enabled expanded use for treating primary antibody deficiency syndromes and autoimmune conditions. Recent advancements include the use of IVIG in secondary immune deficiencies related to hematologic malignancies and stem cell transplantation, along with the newly emerging prophylactic applications following chimeric antigen receptor T-cell (CAR-T) therapies. Novel therapeutic areas such as bispecific antibodies (BsAbs) for lymphoma and myeloma have increased the use of IgG, given the associated risks of infections. Today, the concept of a rational personalized clinical use of IgG in the context of evolving clinical indications in high-income countries (HIC) is emerging, as unmet challenges in line with managing shortages due to increasing demands globally. The current work aims to review and link the indications for IgG to their characteristics and formulations, their dose, route and frequency of administrations and duration of therapy to meet the needs of individual patients. It will also explore the means to rationalize and monitor IgG use in HIC in the time of shortage, while explaining pragmatic strategies to improve supply and use in low- and middle-income countries (LMIC).</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103987"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights","authors":"K. Benmoussa ,&nbsp;F. Bernaudin ,&nbsp;P. Connes ,&nbsp;O. Héquet ,&nbsp;L. Joseph ,&nbsp;M. Beraud ,&nbsp;A. Bah","doi":"10.1016/j.transci.2024.103988","DOIUrl":"10.1016/j.transci.2024.103988","url":null,"abstract":"<div><p>In France, sickle cell disease (SCD) is the most common rare disease and represents the most prevalent genetic disorder, with 19,800 to 32,400 patients diagnosed in 2016 and 1:714 newborns affected in 2019. SCD is caused by a single mutation in the β-globin gene, resulting in the production of abnormal hemoglobin (called HbS), chronic hemolytic anemia, and impaired red blood cell rheology. SCD patients face several severe acute and chronic complications, including stroke, acute chest syndrome (ACS), painful vaso-occlusive crisis (VOC), organ failure, and a high risk of infections. As patients’ care pathway remains unclear in France, a roundtable advisory board meeting was organized in the country to provide insights into the management of SCD in alignment with clinical guidelines. The meeting brought together a panel of esteemed key opinion leaders (KOLs) in SCD management, encompassing both clinical practice and research. During the meeting, the KOLs discussed clinical practices and their alignment with French guidelines, identifying areas of concordance and discrepancy. They also addressed disparities in SCD clinical practices across regions and medical centers. The KOLs discussed the prophylactic and therapeutic options currently available for SCD patients in France, with a focus on transfusion therapies, especially automated red blood cell exchange (aRBCX). The results of this advisory board meeting provide a valuable platform for gathering expert perspectives on SCD management, clinical practices, guideline alignment, and the potential for contributions to guideline updates.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103988"},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1473050224001599/pdfft?md5=fd5cd754b274de5308902235552624b5&pid=1-s2.0-S1473050224001599-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience","authors":"M Sarmiento,&nbsp;J Salinas,&nbsp;P Rojas,&nbsp;C Gutierrez,&nbsp;M Vidal,&nbsp;V Jara,&nbsp;MJ Garcia,&nbsp;MJ Campbell,&nbsp;Y Flores,&nbsp;V Sandoval,&nbsp;M Vergara,&nbsp;F Palacios,&nbsp;M Ocqueteau","doi":"10.1016/j.transci.2024.103983","DOIUrl":"10.1016/j.transci.2024.103983","url":null,"abstract":"<div><p>Adequate stem cell harvesting is required for autologous hematopoietic transplantation. In deficient mobilizer patients, the collection of stem cells can be challenging because of the impossibility of achieving satisfactory CD34 cell counts with GCSF + - chemotherapy. Plerixafor is a potent and expensive drug that promotes the release of stem cells from the medullary niche to the peripheral blood and allows satisfactory harvests. We performed a retrospective analysis of 370 patients with myeloma and lymphoma harvested at our institution. 99 % of patients achieved satisfactory apheresis using Plerixafor in 45 %. Satisfactory harvests were obtained in patients mobilized with GCSF or plerixafor. In patients who used plerixafor, it was necessary to perform fewer apheresis procedures (P = 0.05). In multivariate analysis, the only factor that predicted the need for plerixafor was the presence of less than 30,000 CD34 / ul on the day of apheresis (OR 0.3. p &lt; 0.001). Since we adopted the plerixafor protocol guided by CD34 counts, the number of patients with harvest failure has decreased. In conclusion, the rational and standardized use of plerixafor favors satisfactory harvest in patients who require autologous transplantation in South-American patients.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103983"},"PeriodicalIF":1.4,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guest Editor’s Bio","authors":"Shunya Nakane","doi":"10.1016/j.transci.2024.103966","DOIUrl":"10.1016/j.transci.2024.103966","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 4","pages":"Article 103966"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACKR1 gene polymorphisms in Bombay blood group (Oh) individuals of Indian origin","authors":"Roshan Shaikh ,&nbsp;Ghosh Kanjaksha ,&nbsp;Vasantha Kashivishwanath ,&nbsp;Swati Kulkarni ,&nbsp;Seema Jadhav ,&nbsp;Harita Maru ,&nbsp;Ajit Gorakshakar","doi":"10.1016/j.transci.2024.103975","DOIUrl":"10.1016/j.transci.2024.103975","url":null,"abstract":"<div><h3>Background</h3><p>ACKR1 blood group genes exhibit a high degree of polymorphisms with varying allele distribution seen among different populations and ethnic groups. The study aimed to genotype ACKR1 antigens and to establish FY allele frequency among the individuals with the Bombay (Oh) blood group phenotype.</p></div><div><h3>Materials and methods</h3><p>ACKR1 phenotype and genotype frequencies were estimated on 160 individuals typed as Oh and were compared with 100 non-oh blood donors from Mumbai, India by molecularly genotyping via PCR-RFLP.</p></div><div><h3>Results</h3><p>The allelic and genotypic frequency of T(−67)C polymorphism showed the dominance of T allele and TT genotype [OR= 3.26 (0.59–17.99)] in both the study groups. The ACKR1 null (Fya-b-) phenotype was not found in the tested group. While the genotypic combination among the Oh group individuals was FYA/FYB (45.3 %), FYA/FYA (42.7 %), and FYB/FYB (12 %), in the non-Oh group donors, it was observed as FYA/FYB (53.3 %), FYA/FYA (39.1 %), and FYB/FYB (7.6 %).</p><p>The haplotype TGGGC occurred in 38.4 % of the Oh group, but in non-Oh donors, it was found to be 50.9 % [OR = 1.820 (1.196–2.771)], and the difference was statistically significant (p = 0.005). Similarly, the TGGGT haplotype was found at a frequency of 12.7 % in non-Oh donors and 27.1 % in Oh group [OR= 0.411 (0.234–0.722)] (p = 0.001).</p></div><div><h3>Conclusions</h3><p>This study shows the prevalence of ACKR1 gene polymorphisms, including weak ACKR1 antigens in Oh individuals with a high frequency of haplotype TGGGC. The present study demonstrated for the first time the genotypes FyBweak, FyAweak and Fy Aweak/FyBESon RBC membranes in Indian subjects with Oh phenotype.</p></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"63 5","pages":"Article 103975"},"PeriodicalIF":1.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}